PMC:7736111 / 28885-29096 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"728","span":{"begin":9,"end":13},"obj":"Gene"},{"id":"735","span":{"begin":59,"end":69},"obj":"Species"},{"id":"769","span":{"begin":197,"end":200},"obj":"Gene"},{"id":"770","span":{"begin":117,"end":125},"obj":"Species"},{"id":"771","span":{"begin":159,"end":167},"obj":"Species"},{"id":"776","span":{"begin":108,"end":116},"obj":"Disease"}],"attributes":[{"id":"A728","pred":"tao:has_database_id","subj":"728","obj":"Gene:59272"},{"id":"A735","pred":"tao:has_database_id","subj":"735","obj":"Tax:2697049"},{"id":"A769","pred":"tao:has_database_id","subj":"769","obj":"Gene:3439"},{"id":"A770","pred":"tao:has_database_id","subj":"770","obj":"Tax:9606"},{"id":"A771","pred":"tao:has_database_id","subj":"771","obj":"Tax:9606"},{"id":"A776","pred":"tao:has_database_id","subj":"776","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ds using ACE2 modulators as viable therapeutic options for SARS-CoV-2.\nBased on the recent clinical data on COVID-19 patients, we can infer that mild/moderate patients should possess optimal early IFN response. "}

{"project":"LitCovid-sentences","denotations":[{"id":"T168","span":{"begin":71,"end":210},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ds using ACE2 modulators as viable therapeutic options for SARS-CoV-2.\nBased on the recent clinical data on COVID-19 patients, we can infer that mild/moderate patients should possess optimal early IFN response. "}